Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

March 7, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

1
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

2
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

3
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

4
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

5
September 22, 2023October 1, 2023

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • Appendicitis – Antibiotics or Appendectomy?

SIGN TO START PHASE 1 HUMAN TRIAL OF “ANTISERA”-DCGI

Can PRESENCEOF HYALURONAN be used as a treatment option in COVID19 patients?

Appendicitis – Antibiotics or Appendectomy?
  • BiotechToday
  • World

Appendicitis – Antibiotics or Appendectomy?

bioxone October 7, 2020October 7, 2020

Thota Kanishka Rao, Amity University Kolkata

Appendectomy has for quite some time been the standard treatment for appendicitis, even though effective utilisation of anti-microbial therapy as an option was accounted for over 60 years. Even in recent years, more than 95% of U.S. patients with appendicitis underwent an appendectomy.

However, with the ongoing Covid-19 pandemic, health systems, for example, the American College of Surgeons10 have suggested reevaluation of numerous aspects of care conveyance, remembering the function of antibiotics for the therapy of appendicitis. Researchers conducted the Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) trial to compare antibiotic therapy with appendectomy in adults with appendicitis, including those with an appendicolith.

The trial design depended on the recognition that not all patients prioritise the various results identified with appendicitis care similarly. An overall measure of health status was utilised for the primary outcome, and analysis of several secondary clinical and patient-reported results, complications, and time spent in health care settings were performed. A pragmatic, nonblinded, noninferiority, randomised trial comparing antibiotic therapy (10-day course) with appendectomy in patients with appendicitis at 25 U.S. centres. 

The primary result was 30-day health status, as surveyed with the European Quality of Life–5 Dimensions (EQ-5D) poll (scores run from 0 to 1, with higher scores demonstrating better health status; noninferiority edge, 0.05 points). Secondary results included appendectomy for the antibiotics agents’ group and complications through 90 days; analyses were prespecified in subgroups characterised by the presence or absence of an appendicolith.

Antibiotics were non-inferior to appendectomy based on 30-day EQ-5D scores (mean difference, 0.01 points; 95% confidence interval [CI], −0.001 to 0.03). 

Antibiotic agents were non-inferior to appendectomy based on 30-day EQ-5D scores (mean contrast, 0.01 points; 95% confidence interval [CI], −0.001 to 0.03). In the antibiotics group, 29% had gone through appendectomy by 90 days, incorporating 41% of those with an appendicolith and 25% of those without an appendicolith.

Also read: Complement Tissue injury and its protection during COVID-19

Source:

A Randomized Trial Comparing Antibiotics with Appendectomy for Appendicitis: NEJM New England Journal of Medicine. Author affiliations of the members of the writing committee are as follows: the University of Washington (D.R.F., & Jacobs https://www.nejm.org/doi/full/10.1056/NEJMoa2014320

  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP
  • AI Literacy in Early Childhood Education: Challenges and Opportunities

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged antibiotics antimicrobial therapy appendectomy Appendicitis appendicitis treatment appendicolith appendix clinical research CODA COVID-19 Drug Research European Quality of Life–5 Dimensions (EQ-5D) poll Survey US Patent

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • BiotechToday
  • World

Can PRESENCEOF HYALURONAN be used as a treatment option in COVID19 patients?

bioxone October 7, 2020

Arpita Adhikary, Amity University Kolkata Deterioration of the respiratory system mainly the lungs is prominent in SARS COVID-19. An active agent, a jelly-like substance was found in dead COVID 19 patients’ respiratory system.  A novel fact is established by the researchers as they conducted an experiment comparing the diseased lung tissue of COVID patients and […]

HYALURONAN

Related Post

  • BiotechToday
  • World

Probiotic Lactobacillus Acidophilus: Can cure Intestinal Disorders?

bioxone April 29, 2021April 28, 2021

Husna, Amity University Kolkata Intestinal epithelial tight junctions (TJs) act as a barrier to protect against harmful antigens which promote inflammation of the intestine in case of inflammatory bowel diseases. A defect in the intestinal TJ barrier is sometimes also known as “leaky gut”. Till date, no effective therapies are available for targeting the intestinal […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

COVID-19 to soon face 2 new drugs

bioxone May 30, 2021June 1, 2021

Sampriti Roy, University of Calcutta At this time in the pandemic when we have ongoing vaccination drives, a new development in the pharmaceutical industry could prove to be a step towards enhanced protection and ability to fight against COVID-19 infections. This is the development of two drugs developed by Australian scientists from QIMR Berghofer Medical […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Are Care Home Residents more vulnerable to SARS-CoV-2?

bioxone March 8, 2021March 8, 2021

-Devyani Goswami, Amity University Kolkata One of the parts of the society which remains under huge threat for the spreading of the deadly SARS-CoV-2 is the care homes. Older people with health issues remain to be the vulnerable target of this virus. The shared living accommodations along with residents, staff and visitors in an enclosed […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Exogenous Klotho as a Cognition Booster in Aging Primates

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy